Articles
Personalized change

Personalized change

Nathan Nagel discusses the change in approach to drug development following the increase in personalized medicine. The purpose of this article is to provoke thoughts about how the new paradigm of personalized medicine may...

Articles
Data transparency in clinical trials

Data transparency in clinical trials

Trish Groves of the BMJ offers an overview of the latest news on data transparency in clinical trials. Why should patient level data from clinical trials be shared? The best reasons for data sharing are to optimise the evidence base...

Articles
FDA post-election: continuity and progress likely to mark 2013

FDA post-election: continuity and progress likely to mark 20...

Regulatory expert Steven Grossman shares his views on the recent US Presidential election and how this decision will affect the FDA and the healthcare industry this year. Looking back over the last 40 years at FDA (as I have), there are three characteristics that create a more...

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D